Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Carlos F. Fernandez-Del Castillo, M.D.

Co-Author

This page shows the publications co-authored by Carlos Fernandez-Del Castillo and Jeffrey Clark.
Connection Strength

0.941
  1. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. Pancreatology. 2020 Jun; 20(4):722-728.
    View in: PubMed
    Score: 0.216
  2. Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment. Pancreas. 2017 02; 46(2):183-189.
    View in: PubMed
    Score: 0.174
  3. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy. Eur Radiol. 2022 Apr; 32(4):2470-2480.
    View in: PubMed
    Score: 0.060
  4. Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. Pancreatology. 2021 May 15.
    View in: PubMed
    Score: 0.059
  5. Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Mol Imaging Biol. 2021 06; 23(3):456-466.
    View in: PubMed
    Score: 0.057
  6. Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. Ann Surg Oncol. 2020 Dec; 27(13):5161-5172.
    View in: PubMed
    Score: 0.055
  7. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. Am J Clin Oncol. 2018 07; 41(7):656-661.
    View in: PubMed
    Score: 0.048
  8. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. Am J Clin Oncol. 2018 06; 41(6):607-612.
    View in: PubMed
    Score: 0.048
  9. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017 Oct 01; 23(19):5959-5969.
    View in: PubMed
    Score: 0.045
  10. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):830-8.
    View in: PubMed
    Score: 0.036
  11. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013; 18(5):543-8.
    View in: PubMed
    Score: 0.034
  12. Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e337-43.
    View in: PubMed
    Score: 0.031
  13. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer. 2012 Jun 15; 118(12):3026-35.
    View in: PubMed
    Score: 0.030
  14. Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy. Gastrointest Cancer Res. 2011 Jul; 4(4):116-21.
    View in: PubMed
    Score: 0.030
  15. Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations. Pancreatology. 2005; 5(1):67-74.
    View in: PubMed
    Score: 0.019
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.